A research associate works at the Moderna Therapeutics Inc. lab in Cambridge, Massachusetts, US | Bloomberg
A research associate works at the Moderna Therapeutics Inc. lab in Cambridge, Massachusetts, US | Bloomberg
Text Size:

New York: The Food and Drug Administration’s new standards on Covid-19 vaccine development may dampen Wall Street hopes that a shot to prevent the spread of the pandemic will be available before the U.S. election in November.

With the FDA’s standards for an emergency use authorization not much lower than what’s needed for full approval, the first authorization seems more likely to happen in early 2021, said Geoffrey Porges, an analyst with SVB Leerink.

The agency’s guidance, published on Tuesday, said any vaccine candidate would need to prove itself at least 50% more effective than a placebo to earn an approval, and that merely showing immune response data would not be enough.

“It is hard to see how those studies could enroll thousands of patients, vaccinate them, and then observe them for safety for six months or more, and then be approved” before the end of the year, Porges wrote in a note to clients. A fully approved vaccine will need “extensive safety data, and full clinical efficacy,” he said.

Investors were anticipating the first vaccine might arrive in the autumn after reports of President Donald Trump pressuring health officials in his re-election bid. Drug and vaccine developers including Johnson & Johnson, Merck & Co., Pfizer Inc. and Moderna Inc. are taking part in the administration’s “Warp Speed” program. The government program is meant to further efforts to develop a vaccine faster than any have been developed before, though details are scant.

Pfizer rallied as much as 5.6% on Wednesday after early data with partner BioNTech SE showed promising effects for a vaccine candidate, while small-cap vaccine developer Inovio Pharmaceuticals Inc. plunged 27%. Moderna, one of the leaders in the space, fell 7.9%. All three vaccine programs would likely need longer-term results to clearly establish safety, according to Porges. DNA vaccines in particular, like Inovio’s, may be “held to a more stringent standard given general concerns about risks of genetic integration.”

Porges doesn’t see a 2020 vaccine happening, and “the success of that effort is by no means a foregone conclusion,” he said. Instead, he predicts a full vaccine approval may come in another two or three years, with widespread adoption taking another year after that.

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.

SUBSCRIBE NOW

Should a vaccine be approved, getting enough Americans to vaccinate will be another hurdle to turning the tide on Covid-19. Yesterday’s guidelines are meant to depoliticize the government’s vaccine efforts so people aren’t afraid to get vaccinated, Beacon Policy Advisors founder Brandon Barford said in a phone interview.

“They are trying to put out very prescriptive guidelines so outside experts can quickly try to validate the studies and help with the public health efforts,” Barford said. The stock market has not incorporated “enough analysis surrounding the politics of a vaccine and how even if the science delivers, our political leaders may fail the test by overly politicizing the process to a point that it will take longer than anticipated for a sufficient number of people to agree to be vaccinated to reach herd immunity in the U.S.,” according to Barford.

But the tone of U.S. regulators should put citizens at ease as it “suggests that regardless of political pressure, the FDA continues to apply sound regulatory judgment and expertise to the development of all medical products, particularly vaccines, regardless of the severity of the economic, political, or public health urgency of the current situation,” Porges said, “For that integrity, the general public, the biopharma industry, and all of its investors should be grateful.” – Bloomberg


Also read: Experimental vaccine from Pfizer & BioNtech shows promise in early test


 

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.

Support Our Journalism

Share Your Views

LEAVE A REPLY

Please enter your comment!
Please enter your name here